The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.
0523 GMT - Roche Holding's estimate of the peak sales potential for a new experimental lung-cancer drug seems conservative, Citi analysts say in a research note. The Swiss drugmaker on Thursday said the drug, divarasib, met primary and key secondary goals in a late-stage trial of patients with a type of lung cancer who had been previously treated. The positive trial results represent an important first step toward approval of a medicine that has potential to be another blockbuster, according to Citi. Roche has guided for divarasib annual peak sales of 1 billion to 2 billion Swiss francs. Citi estimates the first trial alone could unlock peak sales of 1.4 billion francs, with two additional studies offering room for potential upgrades. (adria.calatayud@wsj.com)
0519 GMT - Sembcorp Industries' 1H result is likely to be weighed by the Middle East conflict driving up energy prices and a challenging operating environment in India, says Citi analyst Luis Hilado in a note. The U.S.-Iran conflict pushed upstream gas suppliers to raise prices, resulting in margin pressure for the Singapore energy and urban solutions provider, he says. Weather disruption and currency weakness are also dragging down Sembcorp's renewables business in India, he says. He cuts his 2026-2028 recurring and reported profit projections by 6%-11% and 10%-14%, respectively. Citi adds a negative 30-day catalyst watch on Sembcorp's shares and cuts its target price to 6.92 Singapore dollars from S$7.02. It retains its buy rating. Shares drop 3.7% to S$5.96. (megan.cheah@wsj.com)
0501 GMT - Darma Henwa may benefit from securing contracts outside of Bumi Resources, for which it is a core contractor, Bahana Sekuritas's Jeremy Mikael says in a research report. The company has secured its first external mining-services contract, appointed as primary contractor at the Sebuku Sejaka Coal pit at Indonesia's Pulau Laut, the analyst notes. The mandate runs for five years and is extendable to concession expiry, with a scope of up to 5 million tons per year of coal at total value of around 22 trillion rupiah. However, the brokerage cuts the stock's target price to 600.00 rupiah from 850.00 rupiah to partly reflect higher risk premium, with an unchanged buy rating. Shares are 4.7% higher at 314.00 rupiah. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
July 03, 2026 01:23 ET (05:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments